1 active not recruiting, 1 unknown. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Unknown 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Hao Zeng: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy Vorolanib Tablets, Sintilimab Injection - Renal Cell Carcinoma, Immunotherapy | Phase 2 | Unknown | Hao Zeng | 67 | 2024-08-01 | 2024-07-26 |
| A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma AK104, Axitinib - Renal Cell Carcinoma, First-line Treatment | Phase 1 / Phase 2 | Active not recruiting | Hao Zeng | 37 | 2023-11-17 | 2026-04-07 |
Axitinib (1) · sintilimab (1) · vorolanib (1)
China (2)